Lipocine Inc., a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to ...
Lipocine has received clearance from the U.S. Food and Drug Administration (FDA) to clinically investigate LPCN 1144 in an expanded target population of adult male non-alcoholic steatohepatitis (NASH) patients.